Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stake Boosted by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC boosted its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 827,423 shares of the company's stock after purchasing an additional 56,756 shares during the quarter. Establishment Labs makes up 2.0% of Rice Hall James & Associates LLC's investment portfolio, making the stock its 10th largest position. Rice Hall James & Associates LLC owned about 2.87% of Establishment Labs worth $33,763,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Establishment Labs during the 4th quarter valued at about $5,494,000. Swiss National Bank boosted its position in shares of Establishment Labs by 2.7% during the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after acquiring an additional 1,000 shares during the last quarter. Royce & Associates LP bought a new stake in shares of Establishment Labs during the 4th quarter valued at about $4,862,000. William Blair Investment Management LLC boosted its position in shares of Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock valued at $37,447,000 after acquiring an additional 248,888 shares during the last quarter. Finally, Sei Investments Co. boosted its position in shares of Establishment Labs by 22.3% during the 4th quarter. Sei Investments Co. now owns 42,471 shares of the company's stock valued at $1,957,000 after acquiring an additional 7,731 shares during the last quarter. Institutional investors own 72.91% of the company's stock.

Establishment Labs Price Performance

NASDAQ:ESTA traded down $1.21 during mid-day trading on Thursday, reaching $42.45. The stock had a trading volume of 225,475 shares, compared to its average volume of 475,410. The firm has a 50 day moving average price of $39.04 and a two-hundred day moving average price of $36.93. The stock has a market capitalization of $1.23 billion, a P/E ratio of -13.69 and a beta of 0.80. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $50.85. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. The company had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. Establishment Labs's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.58) EPS. As a group, analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Analyst Ratings Changes

ESTA has been the subject of a number of research analyst reports. Citigroup lifted their price target on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Wall Street Zen downgraded Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Mizuho lifted their price target on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday. BTIG Research initiated coverage on Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $54.83.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.